Developer docs
API playgroundTry for free, no card

Search company profiles

Trio Pharmaceuticals

Full company profile

uuid0000cfi

Namestring
Trio Pharmaceuticals
Legal namestring
Trio Pharmaceuticals Inc.
Company typeenum
Private
Founded yearint
2020
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bispecific antibody drugs, antibody-drug conjugates, cancer immunotherapy, oncology therapeutics, dual targeting antibodies
Industry3 codes
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cancer Therapeutics / Oncology Biologics
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Development and Licensing
TypeOne Time License
Description

Pre-revenue biotechnology company developing novel cancer therapeutics. Expected to generate revenue through licensing deals with large pharmaceutical companies, acquisition, or eventual product commercialization upon FDA approval.

triopharmaceuticals.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Operations, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 4 records shown
1TIE-ADC
Description

Tumor Immunity Enhancing Antibody-Drug Conjugate - a first-ever dual targeting ADC that kills both cancer cells and immunosuppressor cells to completely remove immunosuppression in tumors.

triopharmaceuticals.com
+3 more records
Core offering1 text field

Trio Pharmaceuticals develops novel dual-targeting antibody drugs for cancer treatment through two proprietary platforms: TIE-ADC™, a first-ever dual-targeting antibody-drug conjugate that simultaneously kills cancer cells and immunosuppressor cells, and TRAILBody™, an antibody that directly kills cancer cells by activating endogenous cell death while sparing normal cells. The company's pipeline targets hematologic malignancies (AML, MDS) and solid tumors (ovarian, endometrial, TNBC, NSCLC) and is intended to be advanced through clinical development and commercialized via licensing or acquisition by larger pharmaceutical companies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Proof-of-concept demonstrated in animal studies
Product overview1 text field

Trio Pharmaceuticals is developing a portfolio of novel dual-action antibody drugs for cancer treatment. The core products are TRAILBody™ (which directly induces cancer cell death via endogenous pathways without toxicity) and TIE-ADC™ (a dual-targeting antibody-drug conjugate that eliminates both tumor cells and immunosuppressor cells). The company is advancing clinical candidates for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), ovarian cancer, endometrial cancer, triple negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).

Product and service1 record
1TIE-ADC™ (Tumor Immunity Enhancing Antibody-Drug Conjugate™)
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeTechnology or IntegrationAnnounced on2020-04-30
Description

Development collaboration to evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Ajinomoto Bio-Pharma Services, for the development of TRIObody Drug Conjugates (TDCs). This partnership enables site-specific conjugation for TRIO's dual-action antibody therapy platform.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor targeting with immune activation in the tumor microenvironment — the closest mechanistic analog to Trio's TIE-ADC™ dual-targeting concept of killing cancer cells plus immunosuppressor cells.

TypeDirect peer
Description

Clinical-stage ADC platform company developing next-generation antibody-drug conjugates with proprietary payload and conjugation chemistries. Highly comparable pre-clinical/early-clinical stage and indication breadth in oncology.

TypeDirect peer
Description

Clinical-stage biotech with proprietary bispecific antibody platforms (Azymetric™) targeting oncology indications. Directly comparable as a platform bispecific antibody developer pursuing partnerships with large pharma.

TypeDirect peer
Description

Clinical-stage biotech developing bispecific antibodies (DART® and TRIDENT® platforms) for cancer, including hematologic malignancies and solid tumors. Comparable bispecific mechanism, oncology focus, and partnership-driven business model.

TypeDirect peer
Description

Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies. Similar stage, similar modality mix (ADCs + immuno-oncology), and similar licensing-out business model targeting large pharma partnerships.

TypeBroad incumbent
Description

Established ADC pioneer (Elahere/Mirvetuximab) acquired by AbbVie. Comparable as an oncology ADC specialist; broader portfolio and commercial-stage assets make it an incumbent peer rather than a direct head-to-head competitor.

TypeBroad incumbent
Description

Leading bispecific antibody platform company (DuoBody®, HexaBody®) with multiple approved and clinical-stage assets and broad large-pharma partnerships. A broad incumbent rather than a direct competitor; represents the strategic benchmark for bispecific platforms.

TypeEmerging player
Description

Clinical-stage biotech developing next-generation ADCs (including topoisomerase-based payloads) with proprietary conjugation technology. Closely overlapping ADC modality and similar stage/profile to Trio's TIE-ADC program.

9Duality Biologics
TypeEmerging player
Description

Clinical-stage developer of next-generation ADCs with proprietary payload and linker chemistry. Emerging peer with overlapping modality, comparable early-clinical stage, and partnership-heavy business model.

TypeEmerging player
Description

Clinical-stage oncology biotech with Probody® masked antibody platform designed to improve tumor selectivity. Comparable in modality (engineered antibodies for cancer) and partnership-driven development model; complementary rather than head-to-head with TRIO's dual-action approach.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors8 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Trio Pharmaceuticals

Cancer Therapeutics / Oncology Biologicstriopharmaceuticals.com

Trio Pharmaceuticals firmographics

Firmographics
Name
Trio Pharmaceuticals
Legal name
Trio Pharmaceuticals Inc.
Website
https://triopharmaceuticals.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
11–50 employees
Ownership category
akta.pro rank

Trio Pharmaceuticals industry classification

Industry
Product category
Cancer Therapeutics / Oncology Biologics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAAAF
Bispecific & Multispecific Antibodies
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAAAE
Antibody-Drug Conjugates (ADCs) & Antibody Conjugates
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYHLAAAIAB
Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Bispecific antibody drugs
  • Antibody-drug conjugates
  • Cancer immunotherapy
  • Oncology therapeutics
  • Dual targeting antibodies

Where Trio Pharmaceuticals is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Trio Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Others

Revenue model

  1. Drug Development and Licensing: Pre-revenue biotechnology company developing novel cancer therapeutics. Expected to generate revenue through licensing deals with large pharmaceutical companies, acquisition, or eventual product commercialization upon FDA approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Trio Pharmaceuticals product offering

Product offering

Core offering

Trio Pharmaceuticals develops novel dual-targeting antibody drugs for cancer treatment through two proprietary platforms: TIE-ADC™, a first-ever dual-targeting antibody-drug conjugate that simultaneously kills cancer cells and immunosuppressor cells, and TRAILBody™, an antibody that directly kills cancer cells by activating endogenous cell death while sparing normal cells. The company's pipeline targets hematologic malignancies (AML, MDS) and solid tumors (ovarian, endometrial, TNBC, NSCLC) and is intended to be advanced through clinical development and commercialized via licensing or acquisition by larger pharmaceutical companies.

Product overview

Trio Pharmaceuticals is developing a portfolio of novel dual-action antibody drugs for cancer treatment. The core products are TRAILBody™ (which directly induces cancer cell death via endogenous pathways without toxicity) and TIE-ADC™ (a dual-targeting antibody-drug conjugate that eliminates both tumor cells and immunosuppressor cells). The company is advancing clinical candidates for acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), ovarian cancer, endometrial cancer, triple negative breast cancer (TNBC), and non-small cell lung cancer (NSCLC).

Differentiator

Problem solved

Functional benefit

Brands

  • TIE-ADC: Tumor Immunity Enhancing Antibody-Drug Conjugate - a first-ever dual targeting ADC that kills both cancer cells and immunosuppressor cells to completely remove immunosuppression in tumors.
  • TRAILBody
  • TRIObody
  • TDC

Products and services

  • TIE-ADC™ (Tumor Immunity Enhancing Antibody-Drug Conjugate™)

Quantifiable outcome

  • Proof-of-concept demonstrated in animal studies

Companies that use Trio Pharmaceuticals

Customer profile

Segments3 records

Ideal customer profiles1 record

Trio Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Trio Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ajinomoto Bio-Pharma ServicescoreTechnology or Integration · 30 April 2020Development collaboration to evaluate AJICAP™, a proprietary site-specific conjugation technology offered by Ajinomoto Bio-Pharma Services, for the development of TRIObody Drug Conjugates (TDCs). This partnership enables site-specific conjugation for TRIO's dual-action antibody therapy platform.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Trio Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Bolt Biotherapeutics: Clinical-stage biotech developing immune-stimulating antibody conjugates (ISACs) that combine tumor targeting with immune activation in the tumor microenvironment — the closest mechanistic analog to Trio's TIE-ADC™ dual-targeting concept of killing cancer cells plus immunosuppressor cells.
  • Mersana Therapeutics: Clinical-stage ADC platform company developing next-generation antibody-drug conjugates with proprietary payload and conjugation chemistries. Highly comparable pre-clinical/early-clinical stage and indication breadth in oncology.
  • Zymeworks: Clinical-stage biotech with proprietary bispecific antibody platforms (Azymetric™) targeting oncology indications. Directly comparable as a platform bispecific antibody developer pursuing partnerships with large pharma.
  • MacroGenics: Clinical-stage biotech developing bispecific antibodies (DART® and TRIDENT® platforms) for cancer, including hematologic malignancies and solid tumors. Comparable bispecific mechanism, oncology focus, and partnership-driven business model.
  • Pyxis Oncology: Clinical-stage oncology biotech developing antibody-drug conjugates and immunotherapies. Similar stage, similar modality mix (ADCs + immuno-oncology), and similar licensing-out business model targeting large pharma partnerships.

Broad incumbents

  • ImmunoGen: Established ADC pioneer (Elahere/Mirvetuximab) acquired by AbbVie. Comparable as an oncology ADC specialist; broader portfolio and commercial-stage assets make it an incumbent peer rather than a direct head-to-head competitor.
  • Genmab: Leading bispecific antibody platform company (DuoBody®, HexaBody®) with multiple approved and clinical-stage assets and broad large-pharma partnerships. A broad incumbent rather than a direct competitor; represents the strategic benchmark for bispecific platforms.

Emerging players

  • ProfoundBio: Clinical-stage biotech developing next-generation ADCs (including topoisomerase-based payloads) with proprietary conjugation technology. Closely overlapping ADC modality and similar stage/profile to Trio's TIE-ADC program.
  • Duality Biologics: Clinical-stage developer of next-generation ADCs with proprietary payload and linker chemistry. Emerging peer with overlapping modality, comparable early-clinical stage, and partnership-heavy business model.
  • CytomX Therapeutics: Clinical-stage oncology biotech with Probody® masked antibody platform designed to improve tumor selectivity. Comparable in modality (engineered antibodies for cancer) and partnership-driven development model; complementary rather than head-to-head with TRIO's dual-action approach.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights7 records

Customer concentration

Trio Pharmaceuticals social profiles

Digital presence

Trio Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Trio Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles7 records

Trio Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Trio Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Trio Pharmaceuticals

What does Trio Pharmaceuticals do?

Trio Pharmaceuticals develops novel dual-targeting antibody drugs for cancer treatment through two proprietary platforms: TIE-ADC™, a first-ever dual-targeting antibody-drug conjugate that simultaneously kills cancer cells and immunosuppressor cells, and TRAILBody™, an antibody that directly kills cancer cells by activating endogenous cell death while sparing normal cells. The company's pipeline targets hematologic malignancies (AML, MDS) and solid tumors (ovarian, endometrial, TNBC, NSCLC) and is intended to be advanced through clinical development and commercialized via licensing or acquisition by larger pharmaceutical companies.

Is Trio Pharmaceuticals a public or private company?

Trio Pharmaceuticals is a private company. It is classified as venture growth investor backed and is currently operating.

When was Trio Pharmaceuticals founded?

Trio Pharmaceuticals was founded in 2020. It employs 11 to 50 people.

Where is Trio Pharmaceuticals based?

Trio Pharmaceuticals is headquartered in San Diego, United States, in the North America region.

How does Trio Pharmaceuticals make money?

One revenue line is on record: drug Development and Licensing.

Who are Trio Pharmaceuticals's main competitors?

Direct peers on record are Bolt Biotherapeutics, Mersana Therapeutics, Zymeworks, MacroGenics and Pyxis Oncology. Broad incumbents are ImmunoGen and Genmab. Emerging players are ProfoundBio, Duality Biologics and CytomX Therapeutics.

Does Trio Pharmaceuticals have an API?

No public API is recorded for Trio Pharmaceuticals.

What industry is Trio Pharmaceuticals in?

Trio Pharmaceuticals's product category is Cancer Therapeutics / Oncology Biologics. Its primary akta.pro industry code is HLAAAAAF, Bispecific & Multispecific Antibodies, with a secondary code of HLAAAAAE, Antibody-Drug Conjugates (ADCs) & Antibody Conjugates. Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FierceBiotechChutes & Ladders—Former CBER chief Peter Marks leaps to LillyPeter Marks, the former head of the FDA’s Center for Biologics Evaluation and Research, has joined Eli Lilly as senior vice president of molecule discovery and head of infectious disease. Several biotech companies announced leadership changes, including OSE Immunotherapeutics, TRIO Pharmaceuticals, Stoke Therapeutics, and others, with new appointments for key executive roles.citybizTRIO Pharmaceuticals Completes $3.1M Financing RoundTRIO Pharmaceuticals raised $3.1M in a financing round led by Friedman Bioventure Fund, with participation from the Multiple Myeloma Research Foundation. The San Diego biotech will use the funds to accelerate its journey toward clinical trials for its bispecific antibody cancer drugs.Pulse 2.0TRIO Pharmaceuticals: $3.1 Million Raised For Advancing Cancer TherapeuticsTRIO Pharmaceuticals completed a $3.1 million pre-Series A financing round led by Friedman Bioventure Fund, with support from the Myeloma Investment Fund. The funds will accelerate its TRAILBody and TIE-ADC bispecific antibody programs toward clinical trials for cancers like multiple myeloma and acute myeloid leukemia.citybizNuFund Venture Group Invests in TRIO Pharmaceuticals to Advance Next-Generation Cancer ImmunotherapiesNuFund Venture Group announced an investment in TRIO Pharmaceuticals to advance its next-generation cancer immunotherapies. The $2.2 million seed funding round also includes participation from Purdue Ventures, SeedFolio, Friedman Bioventure, and Life Science Angels to support IND-enabling studies for TRIO's TRAIL Body program.SdbnTRIO Pharmaceuticals Completes $3.1 Million Financing Round to Advance Cancer Therapeutics Pipeline – San Diego Biotechnology NetworkTRIO Pharmaceuticals completed a $3.1 million pre-Series A financing round to advance its cancer therapeutics pipeline. The investment was led by the San Diego-based Friedman Bioventure Fund (FBVF). This funding supports the development of the company's bispecific antibody architectures, specifically TRAILBody and TIE-ADC.VC News DailyTRIO Pharmaceuticals Closes $3.1M FinancingTRIO Pharmaceuticals has closed a $3.1 million pre-Series A financing round led by the Friedman Bioventure Fund (FBVF). The investment received additional support from the Multiple Myeloma Research Foundation's venture philanthropy arm, along with NuFund Venture Group and Life Science Angels. This funding supports TRIO's development of bispecific antibodies for cancer treatment.Pulse 2.0Purdue Ventures Invests In TRIO PharmaceuticalsPurdue Ventures invested $250,000 in TRIO Pharmaceuticals, a cancer immunotherapeutics startup, as part of a $2.2 million seed round. The company's antibody-based therapeutics target immunosuppressive cells to enhance antitumor immunity. The investment aims to advance drug candidates and enable future collaborations.dlvr.itPurdue Ventures Invests In TRIO PharmaceuticalsPurdue Ventures has invested $250,000 in TRIO Pharmaceuticals, a cancer immunotherapeutics startup founded by a Purdue University alumnus. This investment is part of a larger $2.2 million seed-funding round that includes contributions from investor groups in the U.S. and Japan such as NuFund Venture Group and Friedman BioVentures. The funding will enable TRIO to advance its antibody-based technology to eliminate immunosuppressive cells and identify drug candidates for further development.San Diego Business JournalTrio Pharmaceuticals Raises $2.2 Million SeedTrio Pharmaceuticals announced a $2.2 million seed funding round led by SeedFolio, NuFund Venture Group, and Friedman BioVentures to advance its dual-action antibody drug platform for cancer treatment. This investment follows a previous SBIR grant and supports the company's development of novel therapies designed to attack tumor cells while suppressing immunosuppressor cells. The funds will significantly accelerate the progression of these candidates from proof-of-concept studies toward clinical trials.NtangelsNewsight Tech Angelsが米国創薬スタートアップ、TRIO pharmaceuticals社へ出資Newsight Tech Angels has invested in TRIO Pharmaceuticals, a cancer immunotherapeutics startup based in California, USA. This seed funding round was led by a syndicate of US angel investors, with NTA being the only Japanese participant, and is intended to enhance TRIO's capabilities for starting clinical trials. NTA aims to leverage its expertise in clinical development to support TRIO's research and facilitate connections with Japanese pharmaceutical companies.